Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...
Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking the latest effort by the big pharma company to diversify its pipeline in the hope of ...
California biotech Replicate Biosciences will receive up to $550 million from Novo Nordisk in an alliance that aims to track down new drugs for obesity and diabetes. The partners will develop new ...
Replicate Inc., a startup making it easier for software teams to build artificial intelligence applications, today exited stealth mode and announced that it has secured $17.8 million in funding. The ...
Replicate, a startup that runs machine learning models in the cloud, today launched out of stealth with $17.8 million in venture capital backing; $12.5 million of the total came from a Series A led by ...
ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to ...
Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth SAN ...
Replicate Bioscience and Novo Nordisk collaborate to develop srRNA-based therapies for obesity, type 2 diabetes, and cardiometabolic diseases. Novo Nordisk receives an exclusive worldwide license to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback